skip to main content

News Archive

Date: 11/04/2013
Researchers from the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain why patients become resistant to this therapy.
Date: 10/31/2013
Researchers from the University of Michigan Comprehensive Cancer Center have identified new proteins that control the function of critical immune cell subsets called T-cells, which are responsible for a serious and often deadly side effect of lifesaving bone marrow transplants.
Date: 10/23/2013
Eric Fearon among 3 U-M faculty members in this year's class.
Date: 10/15/2013
Adrenal cancer researchers at the University of Michigan Comprehensive Cancer Center are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients.
Date: 10/10/2013
Net proceeds from 20th annual "FFANY Shoes on Sale" charitable shoe sale to support breast cancer research, education nationwide.
Date: 10/08/2013
Ann Arbor-area residents have one last opportunity to join the movement to create a world with less cancer and more birthdays by participating in Cancer Prevention Study-3 (CPS-3), a historic study that has the potential to change the face of cancer for future generations.
Date: 10/07/2013
About a quarter of women experience moderate to severe pain for many years after their treatment ends. In many cases, it's a type of pain that is challenging to treat, with few or no effective options.
Date: 10/02/2013
Wolverines and Detroiters walk the runway Oct. 18 to support breast cancer research at the University of Michigan.
Date: 10/02/2013
A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood -- and it can support the cells' growth for further analysis.
Date: 09/25/2013
The University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.